endpts.com·Jun 2, 2026
Biotech startup NewLimit has raised $435 million in funding, reaching a valuation of over $3 billion, and plans to begin human testing for its anti-aging treatments in 2027. This financing marks one of the largest private investments in the biotech sector for 2026.
NewLimit, an anti-aging biotech startup, has successfully raised $435 million, reaching a valuation of over $3 billion, and plans to begin human testing in 2027. This significant funding round highlights the growing investor confidence and market potential in the anti-aging sector, suggesting a strong opportunity for investment and collaboration in this emerging field within biotech.